TBP Advisors’s AbbVie ABBV Stock Holding History

TBP Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-6,564	Closed	-$379K	–	50
2014 Q3	$379K	Buy	6,564 +200	+3%	+$11.1K	0.22%	46
2014 Q2	$359K	Hold	6,364	–	–	0.21%	45
2014 Q1	$327K	Hold	6,364	–	–	0.2%	46
2013 Q4	$336K	Hold	6,364	–	–	0.22%	46
2013 Q3	$285K	Hold	6,364	–	–	0.2%	48
2013 Q2	$263K	Buy	+6,364	New	+$278K	0.18%	53

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return

TBP Advisors's ABBV Position: Q4 2014 in Review

TBP Advisors sold out of AbbVie (ABBV) in Q4 2014, closing a stake of 6,564 shares — an estimated $379K sold.

TBP Advisors first reported a position in ABBV in Q2 2013 and held it in 6 quarters. The position peaked at $379K in Q3 2014. 1,604 funds tracked by Wall St. Rank hold ABBV as of Q4 2014.

TBP Advisors reported no remaining AbbVie position as of Q4 2014 after selling out during the quarter.
TBP Advisors sold 6,564 AbbVie shares in Q4 2014, an estimated $379K.
TBP Advisors first reported a position in AbbVie in Q2 2013 and held it in 6 quarters.
TBP Advisors's AbbVie position peaked at $379K in Q3 2014.
1,604 funds tracked by Wall St. Rank held AbbVie as of Q4 2014.

Based on TBP Advisors's 13F filing for Q4 2014, filed 16 Jan 2015.